人外周血单个核细胞不同克隆成分向内皮祖细胞分化的实验研究

目的:探讨从成人外周血单个核细胞中分离、培养内皮祖细胞(EPCs)的方法以及EPCs的生物学特征。方法:密度梯度离心法获得单个核细胞,用含生长因子的内皮培养基接种于纤连蛋白包被的培养板中。细胞在接种后每2 h去除1次未黏附细胞共2次,然后隔日换液1次,7 d后计数早期克隆。每例血样均分为2等份,1份在获得早期克隆后进行下列实验;另1份持续培养直到晚期克隆出现进行相同实验。流式细胞技术检测细胞表面抗原表达,直接荧光染色法测定细胞结合荆豆凝集素及摄取乙酰化LDL,胶原凝胶细胞种植实验测定体外血管生成功能。结果:早期克隆中心为圆形细胞,周边是放射状排列的纺锤形细胞,再种植不能形成第2代克隆且无体外血管形成功能,细胞表面主要表达CD14和CD45。晚期克隆形态不同于早期克隆,在培养21～28 d间出现,再种植可形成第2代内皮细胞克隆,并能在胶原凝胶中形成管腔样结构。其构成细胞与早期克隆相比CD45、CD14表达显著减少(P<0.01)而CD146表达明显增加(P<0.01),2种克隆的构成细胞在结合植物凝集素和摄取乙酰化LDL方面未存在显著差异。结论:人外周血单个核细胞在内皮培养条件下可形成早期克隆和晚期克隆,早期克隆属于单核细胞系列,晚期克隆细胞具有EPCs的形态和生物学特征。     

从外周血单个核细胞中获得内皮祖细胞的方法学研究

目的 探讨从成人外周血单个核细胞中分离、培养内皮祖细胞(EPCs)的方法以及EPCs的生物学特征.方法 密度梯度离心法获得单个核细胞(MNCs),用含生长因子的内皮培养基接种于纤连蛋白包被的培养板中.分别采用常规方法(A组)和序列黏附法(B组)培养,A组细胞于接种第4天洗去未黏附细胞然后隔日换液1次;B组细胞接种后每2 h去除1次未黏附细胞,共2次.两组细胞均在7 d后计数早期克隆,持续培养直到晚期克隆出现.流式细胞技术检测细胞表面抗原表达,直接荧光染色法测定细胞结合荆豆凝集素及摄取乙酰化低密度脂蛋白,胶原凝胶细胞种植实验测定体外血管生成功能.结果 早期克隆数目的 获得在2组间差异有统计学意义,但序列黏附法获得晚期克隆数目显著增加(P＜0.05),且B组的早期克隆细胞表达CD3显著减少(P＜0.05).晚期克隆形态不同于早期克隆,在培养21～28 d出现,其组成细胞与早期克隆相比CD45、CD14表达显著减少(P＜0.001)而CD146表达明显增加(P＜0.01),只有晚期克隆再种植可形成第二代内皮细胞克隆,并具有体外血管生成功能.两种克隆的构成细胞在结合植物凝集素和摄取乙酰化低密度脂蛋白方面差异无统计学意义.结论 人外周血单个核细胞在内皮培养条件下可形成早期克隆和晚期克隆,早期克隆属于单核细胞系列,无内皮分化功能;晚期克隆细胞具有EPCs的形态和生物学特征,应用序列黏附法可显著提高晚期克隆获得率.     

人脐静脉血内皮祖细胞的分离扩增和生物学特征

目的:探索人脐静脉血内皮祖细胞的分离和扩增条件,并观测其生物学特性.方法:采集人脐静脉血,应用密度梯度离心法,分离其中单个核细胞,流式细胞术检测CD133 CD34 阳性率;利用差速贴壁法(48 h内贴壁和48 h后贴壁)联合内皮细胞专用培养基EGM-2培养细胞,接种于预先包埋了明胶培养瓶或培养板,倒置显微镜观察细胞生长形态和形成集落能力,免疫细胞化学法检测其免疫表型,摄取Ac-LDL和连接UEA-1功能,在生长因子培养体系中诱导其向成熟内皮细胞分化.结果:所获单个核细胞中CD133 CD34 百分比为1.06%;在EGM-2培养体系下可获得2种亚型的内皮祖细胞,即早期内皮祖细胞和晚期增殖性内皮祖细胞.其中48h后贴壁细胞属于早期内皮祖细胞,增殖能力较弱,免疫荧光检测,显示CD14和CD34KDR胞浆呈阳性表达,Ac-LDL UEA-1 功能特征;而48 h内贴壁细胞在10～17 d时可见由单个细胞增殖形成的克隆,呈铺路石样单层排列,增殖力旺盛形成融合状态,形成次集集落;经免疫荧光检测,显示CD133CD34和CD34KDR细胞质呈阳性表达,Ae-LDL UEA-1 功能特征,传代后vWF,CD31呈强阳性表达,是晚期增殖性内皮祖细胞.结论:经人脐静脉血可分离培养获得2种亚型的内皮祖细胞,在特定的培养体系中细胞可由祖细胞表型向成熟内皮细胞分化.     

人脐血内皮祖细胞的体外分离和培养

目的建立一种稳定的体外分离和培养人脐血来源内皮祖细胞的方法。方法采用密度梯度离心法从人脐带血中分离单个核细胞,将其接种至人纤维连接蛋白包被的六孔板中,用EGM-2培养基诱导培养。通过形态学观察、细胞表面特异性抗原、摄取功能和体外血管形成能力对内皮祖细胞进行鉴定。结果细胞形态学观察发现,刚分离的单个核细胞较小,呈圆形,4 d后可见少量的圆形和梭形贴壁细胞,8 d后有明显集落形成,14 d后相邻集落相互融合,呈现出典型铺路石样改变。内皮祖细胞能摄取乙酰化低密度脂蛋白,结合荆豆凝集素1,表达CD34、CD133和血管内皮细胞生长因子受体2,并且具有体外血管生成能力。结论采用密度梯度离心法可从人脐带血中成功分离和培养出内皮祖细胞,以用于相关实验研究。     

人外周血内皮祖细胞的分离培养及鉴定

目的:从人外周血中分离培养内皮祖细胞(EPCs),并探讨其体外诱导培养的条件。方法:密度梯度离心法分离正常人外周血单个核细胞,置于鼠尾胶原包被的培养瓶中进行体外培养,流式细胞术和免疫荧光法检测分化细胞表面特异性抗原标记物的表达。结果:人外周血单个核细胞在鼠尾胶原包被的培养瓶中培养后呈梭形,并表达内皮细胞的特异性抗原CD34和KDR,和干/祖细胞抗原CD133。提示这些培养细胞既具有内皮细胞的表面标志和功能,又具有祖细胞特性。结论:成功从外周血中培养出EPCs。鼠尾胶原可取代EPCs培养中常用的纤维连接蛋白,是体外分离培养外周血EPCs的更节省的一种方法。     

人外周血内皮祖细胞的分离培养及鉴定

目的从人外周血中分离培养内皮祖细胞(EPCs),并探讨其体外诱导培养的条件.方法密度梯度离心法分离正常人外周血单个核细胞,置于鼠尾胶原包被的培养瓶中进行体外培养,流式细胞术和免疫荧光法检测分化细胞表面特异性抗原标记物的表达.结果人外周血单个核细胞在鼠尾胶原包被的培养瓶中培养后呈梭形,并表达内皮细胞的特异性抗原CD34和KDR,和干/祖细胞抗原CD133.提示这些培养细胞既具有内皮细胞的表面标志和功能,又具有祖细胞特性.结论成功从外周血中培养出EPCs.鼠尾胶原可取代EPCs培养中常用的纤维连接蛋白,是体外分离培养外周血EPCs的更节省的一种方法.     

糖基化终产物引起晚期内皮祖细胞功能障碍

目的观察与糖尿病患者血清浓度类似的糖基化终产物修饰的牛血清白蛋白对体外培养脐血来源晚期内皮祖细胞功能的影响并探讨可能机制。方法密度梯度离心法分离脐血中单个核细胞,用差速贴壁法分离、培养晚期内皮祖细胞。流式细胞术、免疫细胞化学染色及荧光标记的乙酰化低密度脂蛋白、植物凝集素被用于鉴定培养的细胞。将晚期糖基化修饰的牛血清白蛋白与晚期内皮祖细胞共同培养24h后,利用噻唑蓝法检测细胞的增殖能力,AnnexinV/PI双染法流式细胞术检测细胞凋亡;Boyden小室法检测血管内皮生长因子趋化的细胞迁移;ECMatirx-gel检测形成毛细血管样网状结构的能力。利用逆转录聚合酶链反应、蛋白免疫印迹法测定糖基化终产物受体mRNA和蛋白表达水平。结果脐血单个核细胞在体外培养过程中先后出现两种细胞:第5～7天出现集落样生长细胞,扩增不明显,存在14天左右即消失,这类细胞被称为"早期内皮祖细胞";10～15天时,逐渐出现20～50个细胞组成的细胞簇,1～3天即可形成大于500个细胞簇,细胞呈铺路石样,可传代,大于95%的细胞免疫表型为CD45-/CD146+/CD105+,表达内皮细胞特有的vWF因子,可摄取乙酰化低密度脂蛋白并可与荆豆凝集素1结合,这类细胞被称为"晚期内皮祖细胞"。50～400mg/L晚期糖基化修饰的牛血清白蛋白与晚期内皮祖细胞共培养24h后,与对照组相比,细胞的增殖能力未见明显变化(P0.05)。当晚期糖基化修饰的牛血清白蛋白浓度大于100mg/L时,与对照组相比,晚期内皮祖细胞的凋亡增加(P0.05)、血管内皮生长因子趋化的迁移以及在ECMatirx-gel上形成新生血管的能力下降(P0.05),糖基化终产物受体mRNA和蛋白表达均增加(P0.05)。结论糖基化终产物通过促进凋亡、抑制迁移及体外形成新生血管的能力引起晚期内皮祖细胞功能障碍,这些影响可能与糖基化终产物上调晚期内皮祖细胞上糖基化终产物受体表达有关。     

改良法分离培养兔骨髓源性早晚期内皮祖细胞

目的探索简单有效分离培养兔骨髓源性内皮祖细胞的方法,并比较两种内皮祖细胞生物学性状。方法 4周龄左右的新西兰兔,于每侧胫骨取骨髓2 mL,密度梯度离心后取单个核细胞接种于培养瓶,48 h后将悬浮的细胞收集再次贴壁,血管内皮生长因子诱导其向内皮祖细胞分化。免疫细胞化学鉴定其表面标志物、免疫荧光功能学测定,对比前后两种贴壁细胞生长状况。结果早期获取的单个核细胞,半小时后就开始贴壁,3天左右即可长出长梭形的细胞,胞体较大,有血岛样克隆形成,随后培养可形成管腔样结构,10天左右即可呈漩涡状融合整个培养瓶,但这种细胞传代能力差,为早期内皮祖细胞;第2次贴壁的晚期细胞于贴壁后呈椭圆形生长,贴壁后5～7天即可出现集落,片状生长,最后呈铺路石样融合,并可连续传至10代以上,为晚期内皮祖细胞。第2次贴壁的内皮祖细胞在分化过程中明显失去CD133+,而CD34+表达有所升高,大部分第1次贴壁内皮祖细胞可以吞噬乙酰化低密度脂蛋白和荆豆凝集素l,第2次贴壁内皮祖细胞功能学鉴定结果与第1次贴壁的结果类似。结论改良后的密度梯度离心法结合差速贴壁法能有效分离培养兔骨髓源性内皮祖细胞,第2次贴壁的内皮祖细胞生长能力更强。     

内皮祖细胞对血管紧张素Ⅱ诱导的血管平滑肌细胞表型转化的影响

目的 观察内皮祖细胞对血管紧张素Ⅱ诱导的血管平滑肌细胞表型转化的影响.方法 采用6%羟乙基淀粉沉降法和密度梯度离心法分离人脐血单个核细胞,EGM-2细胞培养基进行培养,诱导单个核细胞贴壁向内皮祖细胞分化.采用荧光显微镜双染色、流式细胞术鉴定内皮祖细胞,间接免疫荧光检测血管平滑肌细胞标志物平滑肌α-肌动蛋白、钙调节蛋白的表达,采用逆转录聚合酶链反应和免疫印迹检测早期内皮祖细胞条件培养液、晚期内皮祖细胞条件培养液以及人脐静脉内皮细胞条件培养液对血管紧张素Ⅱ诱导的血管平滑肌细胞收缩表型标志基因平滑肌α-肌动蛋白以及合成表型标志基因骨桥蛋白表达变化的影响.结果 与对照组比较,血管紧张素Ⅱ(10-6mmol/L)诱导血管平滑肌细胞增殖48 h后,平滑肌α-肌动蛋白mRNA和蛋白表达明显减少,而骨桥蛋白mRNA和蛋白表达明显增加,提示血管平滑肌细胞从收缩表型向合成表型转化;与血管紧张素Ⅱ组比较,早期内皮祖细胞条件培养液、晚期内皮祖细胞条件培养液以及人脐静脉内皮细胞条件培养液处理后均不同程度抑制血管紧张素Ⅱ诱导的平滑肌α-肌动蛋白表达减少和骨桥蛋白表达增加,其中以早期内皮祖细胞条件培养液的抑制效果最明显.结论 内皮祖细胞能够抑制血管紧张素Ⅱ诱导的血管平滑肌细胞从收缩表型向合成表型转化.     

脐血、外周血内皮祖细胞分化成内皮细胞的实验研究

目的探讨人的脐血、外周血内皮祖细胞（endothelialprogenitorcells,EPCs）体外分离、纯化、诱导扩增和分化为内皮细胞的可行性,并检测其表型和功能。方法新鲜脐血和健康成年人的外周血,使用Ficoll密度梯度离心法得单个核细胞,在M199培养基中体外培养,3d后去除悬浮细胞,继续培养,诱导EPCs增殖和分化。流式细胞仪检测EPCs标志CD34和内皮细胞特异性标志CD31表型,RTPCR检测ecNOS,flk1/KDR基因水平表达,免疫组化验证蛋白水平表达,并进一步通过NO活性的变化检测内皮细胞的功能。结果流式细胞仪检测,外周血单个核细胞（peripheralbloodmononuclearcells,PBMC）刚分离时,CD34阳性表达率为（1.1±0.8）%,培养3d后为（16.9±6.2）%。细胞形态观察发现,刚分离的单个核细胞呈圆形,形态小,3d后有明显集落形成,7d后梭形细胞线样排列,随培养时间增加,细胞形态逐渐变大,呈现出典型铺路石样改变。脐血单个核细胞（umbilicalcordbloodmononuclearcells,CBMC）和PBMC培养10d后,CD31阳性表达率分别为（76±17）%和（82±9）%。RTPCR检测有内皮细胞特异性成分ecNOS,flk1/KDR的表达。免疫组化染色,细胞膜和细胞浆中有弥漫性棕色出现,呈阳性反应,证实了蛋白水平的表达。培养10d的贴壁细胞随着VEGF浓度增加,NO生成增加,具有内皮细胞的功能。结论脐血,外周血EPCs体外分离,纯化,诱导培养后的贴壁细胞表型检测,大部分细胞具有内皮系标志物,并具有产生NO功能。     

晚期内皮祖细胞在纳米聚-L-乳酸支架膜表面的粘附和增殖

目的通过比较晚期内皮祖细胞在纳米无序及有序聚-L-乳酸支架膜表面粘附、增殖情况,为优化组织工程材料提供一种新途径。方法通过静电纺丝技术制备纳米聚-L-乳酸纤维支架,行低温等离子体技术改性及I型胶原表面涂覆,与晚期内皮祖细胞复合培养,并进行细胞双荧光染色鉴定,通过不同时间点两组材料晚期内皮祖细胞粘附和增殖率的测定比较及光镜、荧光显微镜和扫描电镜观察支架材料对种子细胞形态特征等方面的影响。结果制得的纳米聚-L-乳酸纤维孔径在300～400nm之间,孔隙率>90%;细胞粘附12h基本完成;各时间点有序膜组增殖率明显高于无序膜组(P<0.05)。细胞在支架膜上生长良好,无序膜组细胞生长较散在、杂乱;有良好空间定向效果的有序纤维支架有利于细胞沿纤维定向附着、伸展、增殖,分泌胞外基质。结论晚期内皮祖细胞是理想的组织工程种子细胞来源;纳米聚-L-乳酸有序膜支架能促进种子细胞在材料表面的粘附、增殖,并能较好地保持细胞形态,是一种理想的血管组织工程支架材料。     

Endothelial progenitor cells: isolation and characterization

Bone marrow of adults contains a subtype of progenitor cells that have the capacity to differentiate into mature endothelial cells and have therefore been termed endothelial progenitor cells (EPCs). Of the three cell markers (CD133, CD34, and the vascular endothelial growth factor receptor 2) that characterize the early functional EPCs, located predominantly in the bone marrow, EPCs obviously lose CD133/CD34 and start to express CD31, vascular endothelial cadherin, and von Willebrand factor when migrating to the circulation. Various isolation procedures of EPCs from different sources by using adherence culture or magnetic microbeads have been described, but published findings with regard to the number of EPCs in the peripheral circulation of healthy adults are scanty and no data regarding the lifetime of EPCs in vivo exist. Clinical studies employing EPCs for neovascularization of ischemic organs have just been started; however, the mechanisms stimulating or inhibiting the differentiation of bone marrow-derived EPCs in vivo and the signals causing their adhesion, migration, and homing to sites of injured tissue are largely unknown at present.     

Involvement of progenitor cells in vascular repair

Whereas the genesis of an arterial lesion is thought to be the result of migration and proliferation of vascular cells, recent insights into the biology of progenitor cells now question this concept. Specifically, endothelial and smooth muscle cells appear to be derived from multiple sources such as circulating stem and progenitor cells, as well as tissue-resident progenitor cell populations. These cells may engraft at sites of vascular injury and play an integral role in vascular repair. In this review, experimental data from in vitro studies, animal models, and scattered human observations are reviewed in the context of emerging hypotheses regarding the response to vascular injury.     

Differentiation of endothelial cells from human umbilical cord blood AC133−CD14+ cells

Endothelial progenitor cells (EPCs) participate in neovascularization and are consistent with postnatal vasculogenesis. In vitro, they differentiate into endothelial cells (ECs). Prior reports have suggested that circulating human AC133(+) cells have the capacity to differentiate into ECs as progenitor cells. However, recent studies have demonstrated that circulating CD34(-)CD14(+) cells also have EPC-like properties in vitro and in vivo. We tested whether AC133(-)CD14(+) cells from human umbilical cord blood (HUCB) have the potential to differentiate into ECs. The AC133(-)CD14(+) cells were isolated from HUCB by magnetic bead selection and cultured on fibronectin-coated six-well trays in M199 medium supplemented with fetal bovine serum (FBS), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and insulin growth factor (IGF-1). The AC133(-)CD14(+) cells adhered slightly within 1 day of culture and subsequently underwent a distinct process of morphological transformation to spindle-shaped cells that sprouted from the edge of the cell clusters. After 14 days, the cells formed cord- and tubular-like structures. The AC133(-)CD14(+) cells showed a strong increase in the endothelial marker P1H12 over time, whereas CD14 decreased, and CD45 did not change, respectively. In addition, the cells expressed endothelial markers von Willebrand's factor (vWF), platelet/endothelial cell adhesion molecule-1 (PECAM-1), vascular endothelial growth factor receptor-1 (VEGFR-1)/Flt-1, VEGFR-2/Flk-1, eNOS, and VE-cadherin, but did not express Tie-2 after 7 days of culture. The present data indicate that AC133(-)CD14(+) cells from HUCB are able to develop endothelial phenotype with expression of endothelial-specific surface markers and even form cord- and tubular-like structures in vitro as progenitor cells.     

Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals

The limited vessel-forming capacity of infused endothelial progenitor cells (EPCs) into patients with cardiovascular dysfunction may be related to a misunderstanding of the biologic potential of the cells. EPCs are generally identified by cell surface antigen expression or counting in a commercially available kit that identifies "endothelial cell colony-forming units" (CFU-ECs). However, the origin, proliferative potential, and differentiation capacity of CFU-ECs is controversial. In contrast, other EPCs with blood vessel-forming ability, termed endothelial colony-forming cells (ECFCs), have been isolated from human peripheral blood. We compared the function of CFU-ECs and ECFCs and determined that CFU-ECs are derived from the hematopoietic system using progenitor assays, and analysis of donor cells from polycythemia vera patients harboring a Janus kinase 2 V617F mutation in hematopoietic stem cell clones. Further, CFU-ECs possess myeloid progenitor cell activity, differentiate into phagocytic macrophages, and fail to form perfused vessels in vivo. In contrast, ECFCs are clonally distinct from CFU-ECs, display robust proliferative potential, and form perfused vessels in vivo. Thus, these studies establish that CFU-ECs are not EPCs and the role of these cells in angiogenesis must be re-examined prior to further clinical trials, whereas ECFCs may serve as a potential therapy for vascular regeneration.     

Abnormal blood vessels formed by human liver cavernous hemangioma endothelial cells in nude mice are suitable for drug evaluation

Cavernous hemangioma is vascular malformation with developmental aberrations. It was assumed that the abnormality of endothelial cells contributed greatly to the occurrence of cavernous hemangioma. In our previous study, we have found distinct characteristics of endothelial cells derived from human liver cavernous hemangioma (HCHEC). Here, we reported the abnormal vascular vessels formed by primary HCHEC in nude mice and that the drug podophyllotoxin can destroy HCHEC in vitro and in vivo. HCHEC was isolated from a human liver cavernous hemangioma specimen, and the HCHEC generated a red hemangioma-like mass 7 days after subcutaneously co-inoculating HCHEC and human liver cancer cells (Bel-7402) in nude mice. Lentiviral expression of GFP and immunohistochemistry for human CD31 was used to confirm that the HCHEC formed the blood vessels in nude mice. And the pathological features of vascular vessels formed by HCHEC were very similar to clinical cavernous hemangioma. In addition, by MTT assay, the drug podophyllotoxin was found inhibiting HCHEC viability, and by TUNEL and DNA ladder assays, podophyllotoxin was found inducing apoptosis of HCHEC. Moreover, podophyllotoxin was also effective for destroying the abnormal vascular vessels in the hemangioma-like mass in nude mice. In summary, the HCHEC can form abnormal blood vessels in nude mice, and we can evaluate drugs for cavernous hemangioma by using HCHEC in vitro and in vivo.     

Diverse origin and function of cells with endothelial phenotype obtained from adult human blood

Cells with endothelial phenotype generated from adult peripheral blood have emerging diagnostic and therapeutic potential. This study examined the lineage relationship between, and angiogenic function of, early endothelial progenitor cells (EPCs) and late outgrowth endothelial cells (OECs) in culture. Culture conditions were established to support the generation of both EPCs and OECs from the same starting population of peripheral blood mononuclear cells (PBMCs). Utilizing differences in expression of the surface endotoxin receptor CD14, it was determined that the vast majority of EPCs arose from a CD14+ subpopulation of PBMCs but OECs developed exclusively from the CD14- fraction. Human OECs, but not EPCs, expressed key regulatory proteins endothelial nitric oxide synthase (eNOS) and caveolin-1. Moreover, OECs exhibited a markedly greater capacity for capillary morphogenesis in in vitro and in vivo matrigel models, tube formation by OECs being in part dependent on eNOS function. Collectively, these data indicate lineage and functional heterogeneity in the population of circulating cells capable of assuming an endothelial phenotype and provide rationale for the investigation of new cell-therapeutic approaches to ischemic cardiovascular disease.     

Endothelial progenitors

The studies carried out during the last two decades have represented a great effort in trying to identify and define cell populations endowed with the phenotypic and functional properties of endothelial progenitors. From these studies a scenario now emerges indicating that in the blood there are very rare endothelial progenitor cells, called endothelial colony-forming cells (ECFCs) or late outgrowth endothelial cells, not originated from bone marrow, capable of generating phenotypically and functionally competent endothelial cells, capable to be incorporated in vivo into growing vessels. ECFCs are present in the circulation as well as cells resident in the vascular endothelial intima. In addition to these progenitors, there are some hematopoietic progenitor cells capable of generating a monocytic cell progeny exerting a pro-angiogenic activity in vivo, but unable to be directly incorporated into growing vessels. These cells exert a pro-angiogenic effect in vivo through a paracrine mechanism based on the secretion of growth factors and cytokines.     

粒细胞—巨噬细胞集落刺激因子对大鼠内皮祖细胞功能活性的影响

目的研究粒细胞—巨噬细胞集落刺激因子对内皮祖细胞功能活性的影响,为探讨血管内皮再生修复机制和心血管疾病的防治提供实验基础。方法首先用密度梯度离心法分离培养大鼠骨髓和脾内皮祖细胞,在倒置相差显微镜下观察内皮祖细胞的生长分化过程。标记FITC-AC133和PE-vWF鉴定内皮祖细胞,在荧光显微镜下观察。然后选取培养7d的内皮祖细胞施加实验因素。分别用MTT比色法、Transwell小室、Matrigel管腔形成的体外模型检测粒细胞—巨噬细胞集落刺激因子对内皮祖细胞增殖、迁移、管腔形成能力的影响。结果与对照组相比,粒细胞—巨噬细胞集落刺激因子作用后,内皮祖细胞的OD490值、迁移的细胞数和形成的管腔数显著增加(P<0.001),且随着作用浓度的增加和作用时间的延长内皮祖细胞的OD490值、迁移的细胞数和形成的管腔数逐渐增加。结论在体外,粒细胞—巨噬细胞集落刺激因子能够增强内皮祖细胞的增殖、迁移和管腔形成能力,并随着作用浓度的增加和作用时间的延长其效应增强。